[go: up one dir, main page]

DELLA SALA et al., 2024 - Google Patents

Development and Characterization of PI3Kg/PKA Peptide Disruptors as New Therapeutic Tools for the Treatment of Obstructive Airway Diseases

DELLA SALA et al., 2024

View PDF
Document ID
3516916523279558751
Author
DELLA SALA A
et al.
Publication year

External Links

Snippet

Progressive obstructive airway diseases, including asthma, chronic obstructive pulmonary disease, and the genetic disorder cystic fibrosis (CF), represent a major health burden worldwide. Cyclic AMP (cAMP) elevating agents, like β2-adrenergic receptor agonists and …
Continue reading at iris.unito.it (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Roe et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
Groneberg et al. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport
US8846742B2 (en) Neuronal pain pathway modulators
CN109248310B (en) Blockade of inflammatory proteases using theta-defensins
US20190031730A1 (en) Formulation of mk2 inhibitor peptides
US20140322332A1 (en) Antagonists of muc1
Gomes dos Reis et al. Advances in the use of cell penetrating peptides for respiratory drug delivery
Ferrera et al. Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: An unprecedented property of antimicrobial peptides
JP6975535B2 (en) Drug delivery enhancer
Zheng et al. Supramolecular nanofibers ameliorate Bleomycin‐induced pulmonary fibrosis by restoring autophagy
EP3530278A2 (en) Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
US11407788B2 (en) Prostate-specific membrane antigen (PSMA) targeting peptides
US20200223888A1 (en) Dpep-1 binding agents and methods of use
US9447157B2 (en) Nitration shielding peptides and methods of use thereof
Bae et al. Peptide‐Drug Conjugate with Statistically Designed Transcellular Peptide for Psoriasis‐Like Inflammation
DELLA SALA Development and Characterization of PI3Kg/PKA Peptide Disruptors as New Therapeutic Tools for the Treatment of Obstructive Airway Diseases
EP4192843A1 (en) Peptides able to bind angiotensin-converting enzyme 2 (ace2) and medical uses thereof
Chatterjee et al. A stapled POL κ peptide targets REV1 to inhibit mutagenic translesion synthesis
Della Sala et al. A nonnatural peptide targeting the A-kinase anchoring function of PI3Kγ for therapeutic cAMP modulation in pulmonary cells
AU2015346371A1 (en) Isoform-specific calpain inhibitors, methods of identification, and uses thereof
US8110551B2 (en) Cytolethal distending toxin and use thereof
EP3033094A1 (en) Map kinase p38 binding compounds
WO2022241167A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
WO2025113859A1 (en) "NON-NATURAL PEPTIDES TARGETING THE SCAFFOLD ACTIVITY OF PI3Kγ AND THERAPEUTIC USES THEREOF"
CN110520144A (en) Peptide kinase inhibitors and methods of use